AbCellera Biologics has delivered 96% year-over-year revenue growth and beaten EPS estimates in 3 of the last 4 quarters, but the thesis hinges on whether the current cash burn — negative free cash flow at roughly 144% of revenue — narrows fast enough to allow quality metrics to recover; until it does, the stock remains speculative despite a favorable long-term risk/reward geometry.
Thesis pillars
- Industry Leading Revenue Growth→Stable
- Earnings Beat Consistency→Stable
- Negative Fcf Quality Ceiling→Stable
- +1 more pillar — see the Why tab for full reasoning
AbCellera Biologics Inc. (ABCL) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $8.17: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor... Read more
Sell if holding. Engine safety override at $8.17: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-29Recent Developments — AbCellera Biologics Inc.
Latest news
- NEWS Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration — benzinga Jun 17, 2026 positive
- NEWS Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop — benzinga Jun 17, 2026 positive
- NEWS 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga May 11, 2026 neutral
- NEWS AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate — benzinga May 11, 2026 positive
- NEWS Earnings Scheduled For May 11, 2026 — benzinga May 11, 2026 neutral
Generated 2026-06-29T23:58:55Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $8.17: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: High short interest: 19%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $7.55. Score 5.8/10, moderate confidence.
Take-profit target: $9.07 (+11.7% upside). Prior stop was $7.55. Stop-loss: $7.55.
Quality below floor (2.5 < 4.0).
AbCellera Biologics Inc. trades at a P/E of N/A (forward -10.3). TrendMatrix value score: 3.6/10. Verdict: Sell.
15 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $10.
What does AbCellera Biologics Inc. do?AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet...
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.